Home » Topics » Patents, BioWorld Science

Patents, BioWorld Science
RSS

The Vanderbilt University divulges new muscarinic M5 receptor antagonists

Jan. 10, 2022

Dana-Farber Cancer Institute patents UCP1 activators

Jan. 10, 2022

Wigen Biomedicine Technology synthesizes new Wee1 inhibitors

Jan. 7, 2022

Chinese researchers describe new GLP-1 receptor agonists

Jan. 7, 2022

Anaxis Pharma identifies new RIPK1 and/or MLKL inhibitors

Jan. 7, 2022

Janssen Pharmaceutica discloses Mcl-1 inhibitors

Jan. 7, 2022

French researchers patent new antibacterial compounds

Jan. 7, 2022

Merck & Co. synthesizes RIPK1 inhibitors

Jan. 5, 2022

Vertex Pharmaceuticals identifies new APOL1 inhibitors

Jan. 5, 2022

Novartis presents new Cav1.2 activators

Jan. 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...